Logo image of IVA

INVENTIVA SA - ADR (IVA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IVA - US46124U1079 - ADR

4.21 USD
-0.06 (-1.41%)
Last: 12/9/2025, 9:50:17 AM
Fundamental Rating

1

Overall IVA gets a fundamental rating of 1 out of 10. We evaluated IVA against 531 industry peers in the Biotechnology industry. IVA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, IVA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IVA had negative earnings in the past year.
In the past year IVA has reported a negative cash flow from operations.
In the past 5 years IVA always reported negative net income.
In the past 5 years IVA always reported negative operating cash flow.
IVA Yearly Net Income VS EBIT VS OCF VS FCFIVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -154.84%, IVA is doing worse than 86.63% of the companies in the same industry.
Industry RankSector Rank
ROA -154.84%
ROE N/A
ROIC N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVA Yearly ROA, ROE, ROICIVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

IVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IVA Yearly Profit, Operating, Gross MarginsIVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IVA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IVA has been increased compared to 5 years ago.
The debt/assets ratio for IVA has been reduced compared to a year ago.
IVA Yearly Shares OutstandingIVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IVA Yearly Total Debt VS Total AssetsIVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.01, we must say that IVA is in the distress zone and has some risk of bankruptcy.
IVA's Altman-Z score of -5.01 is on the low side compared to the rest of the industry. IVA is outperformed by 63.47% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.01
ROIC/WACCN/A
WACC7.86%
IVA Yearly LT Debt VS Equity VS FCFIVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 0.92 indicates that IVA may have some problems paying its short term obligations.
IVA has a Current ratio of 0.92. This is amonst the worse of the industry: IVA underperforms 88.70% of its industry peers.
A Quick Ratio of 0.92 indicates that IVA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.92, IVA is doing worse than 88.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.92
IVA Yearly Current Assets VS Current LiabilitesIVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

IVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.14%.
The Revenue for IVA has decreased by -12.84% in the past year. This is quite bad
Measured over the past years, IVA shows a small growth in Revenue. The Revenue has been growing by 5.62% on average per year.
EPS 1Y (TTM)-74.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%

3.2 Future

IVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.26% yearly.
IVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.56% yearly.
EPS Next Y43.78%
EPS Next 2Y24.76%
EPS Next 3Y14.52%
EPS Next 5Y16.26%
Revenue Next Year-15.08%
Revenue Next 2Y-39.27%
Revenue Next 3Y62.43%
Revenue Next 5Y123.56%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IVA Yearly Revenue VS EstimatesIVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
IVA Yearly EPS VS EstimatesIVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IVA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVA Price Earnings VS Forward Price EarningsIVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVA Per share dataIVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as IVA's earnings are expected to grow with 14.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.76%
EPS Next 3Y14.52%

More info and screens

0

5. Dividend

5.1 Amount

IVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVENTIVA SA - ADR

NASDAQ:IVA (12/9/2025, 9:50:17 AM)

4.21

-0.06 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2025-11-21
Earnings (Next)02-16 2026-02-16/amc
Inst Owners43.01%
Inst Owner Change3.62%
Ins Owners4.97%
Ins Owner ChangeN/A
Market Cap804.19M
Revenue(TTM)13.61M
Net Income(TTM)-184.21M
Analysts87.14
Price Target14.44 (242.99%)
Short Float %0.18%
Short Ratio1.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.39%
PT rev (3m)51.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)29.71%
EPS NY rev (3m)-83.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-76.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 75.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.4
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.06
BVpS-0.65
TBVpS-0.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -154.84%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.41%
Cap/Sales 3.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.92
Altman-Z -5.01
F-Score3
WACC7.86%
ROIC/WACCN/A
Cap/Depr(3y)20.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.77%
Cap/Sales(5y)20.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
EPS Next Y43.78%
EPS Next 2Y24.76%
EPS Next 3Y14.52%
EPS Next 5Y16.26%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%
Revenue Next Year-15.08%
Revenue Next 2Y-39.27%
Revenue Next 3Y62.43%
Revenue Next 5Y123.56%
EBIT growth 1Y6.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.14%
EBIT Next 3Y3.93%
EBIT Next 5Y21.53%
FCF growth 1Y-5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.29%
OCF growth 3YN/A
OCF growth 5YN/A

INVENTIVA SA - ADR / IVA FAQ

What is the ChartMill fundamental rating of INVENTIVA SA - ADR (IVA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to IVA.


What is the valuation status of INVENTIVA SA - ADR (IVA) stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA - ADR (IVA). This can be considered as Overvalued.


Can you provide the profitability details for INVENTIVA SA - ADR?

INVENTIVA SA - ADR (IVA) has a profitability rating of 0 / 10.


How financially healthy is INVENTIVA SA - ADR?

The financial health rating of INVENTIVA SA - ADR (IVA) is 0 / 10.